Compare ZS & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZS | BIIB |
|---|---|---|
| Founded | 2007 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0B | 24.2B |
| IPO Year | 2018 | 1991 |
| Metric | ZS | BIIB |
|---|---|---|
| Price | $236.40 | $174.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 34 | 22 |
| Target Price | ★ $323.73 | $177.40 |
| AVG Volume (30 Days) | ★ 2.4M | 2.0M |
| Earning Date | 11-25-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 10.97 |
| Revenue | $2,833,272,000.00 | ★ $10,065,900,000.00 |
| Revenue This Year | $26.93 | $3.61 |
| Revenue Next Year | $19.33 | N/A |
| P/E Ratio | ★ N/A | $15.86 |
| Revenue Growth | ★ 23.24 | 4.77 |
| 52 Week Low | $164.78 | $110.04 |
| 52 Week High | $336.99 | $185.17 |
| Indicator | ZS | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 26.17 | 55.41 |
| Support Level | $237.77 | $169.24 |
| Resistance Level | $245.12 | $180.79 |
| Average True Range (ATR) | 7.41 | 5.36 |
| MACD | -0.93 | -1.56 |
| Stochastic Oscillator | 4.27 | 33.70 |
Zscaler is a software-as-a-service, or SaaS, firm focusing on providing cloud-native cybersecurity solutions to primarily enterprise customers. Zscaler's offerings can be broadly partitioned into Zscaler Internet Access, which provides secure access to external applications, and Zscaler Private Access, which provides secure access to internal applications. The firm is headquartered in San Jose, California, and went public in 2018.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).